DBL Vincristine Sulfate

DBL Vincristine Sulfate

vincristine sulfate




Zuellig Pharma


Concise Prescribing Info
Vincristine sulfate
Acute leukemia. In combination w/ other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular & diffuse types), rhabdomyosarcoma, neuroblastoma, Wilm's tumour, osteogenic & Ewing's sarcoma, mycosis fungoides, uterine cervix & oat-cell lung carcinoma, breast cancer, malignant melanoma & gynaecological childhood tumours.
Dosage/Direction for Use
Adult 0.4-1.4 mg/m2 at wkly intervals. Childn >10 kg or >1 m2 1.5-2 mg/m2 at wkly intervals, ≤10 kg or ≤1 m2 0.05 mg/kg once wkly.
Hypersensitivity to vincristine, vinca alkaloids. Demyelinating form of Charcot-Marie-Tooth syndrome. Concurrent radiation therapy through ports including liver. Lactation.
Special Precautions
Not to be given IM, SC or intrathecally. Avoid extravasation. Leucopenia or complicating infection, history of gout or urate renal stones, spinal cord irradiation, neurological disease, previous cytotoxic drug therapy or irradiation, preexisting neuromuscular disease, herpes zoster or existing or recent chicken pox. Avoid eye contamination. Concomitant neurotoxic agents, mitomycin. Postpone immunisation w/ oral polio vaccines. Hepatic impairment, jaundice. Women of childbearing potential. Pregnancy. Not to be used during lactation. Elderly.
Adverse Reactions
Alopecia; neurotoxicity; leucopenia, neuritic pain, constipation; sensory loss, paraesthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes, muscle wasting; GI & genitourinary disorders; HTN, hypotension; neurological, endocrinal & haematological effects; depression, agitation, insomnia, hallucinations; fever, headache.
Drug Interactions
Increased cytotoxic induced bone marrow depression w/ allopurinol. Raised blood uric acid conc. Additive neurotoxicity w/ asparaginase, INH, other peripheral nervous system drugs. Increased myelosuppression w/ doxorubicin & prednisone. Increased methotrexate cellular uptake. Potentiated vaccine virus replication. Decreased antimicrobial effect of oral quinolones eg, ciprofloxacin, norfloxacin, ofloxacin. Reduced anticonvulsant blood levels & increased seizure activity. Decreased clearance by nifedipine. Decreased metabolism by CYP450 inhibitors. Decreased digitalis glycoside absorption. Increased incidence of acute breath shortness & severe bronchospasm w/ mitomycin. Temporary or permanent hearing impairment w/ potentially ototoxic drugs eg, platinum-containing antineoplastics. Thromboembolism or Raynaud's syndrome w/ bleomycin & other agents eg, cisplatin, etoposide.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CA02 - vincristine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.
DBL Vincristine Sulfate inj 1 mg/mL
2 mL x 1's
DBL Vincristine Sulfate inj 2 mg/2 mL
2 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in